June 17 (Reuters) - Verve Therapeutics Inc ( VERV ):

* LILLY TO ACQUIRE VERVE THERAPEUTICS TO ADVANCE ONE-TIME

TREATMENTS FOR PEOPLE WITH HIGH CARDIOVASCULAR RISK

* ELI LILLY ( LLY ) - PROPOSED DEAL FOR PURCHASE PRICE OF $10.50 PER

SHARE

IN CASH

* ELI LILLY ( LLY ) - PROPOSED DEAL FOR A TOTAL POTENTIAL

CONSIDERATION OF

UP TO $13.50 PER SHARE IN CASH WITHOUT INTEREST

* ELI LILLY ( LLY ) - TRANSACTION IS NOT SUBJECT TO ANY FINANCING

CONDITION

* ELI LILLY ( LLY ): CVR HOLDERS WOULD BE ENTITLED TO GET CONTINGENT

PAYMENT UPON FIRST PATIENT BEING DOSED WITH VERVE-102 FOR ASCVD

IN U.S. PHASE 3 TRIAL

Source text:

Further company coverage: